Answers are grounded in this paper and cite their sources.
// Hui Lyu 1, 2 , Xiao He Yang 3 , Susan M. Edgerton 2 , Ann D. Thor 2 , Xiaoying Wu 4 , Zhimin He 1 , Bolin Liu 1, 2 1 Cancer Research Institute and Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China 2 Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 3 Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Kannapolis, NC, USA 4 Department of Pathology, Xiangya Hospital, School of Basic Medical Science, Central South University, Changsha, China Correspondence to: Bolin Liu, e-mail: bolin.liu@ucdenver.edu Keywords: ErbB3, IGF-1R, lapatinib, trastuzumab, resistance Received: June 20, 2015 Accepted: November 16, 2015 Published: November 26, 2015 ABSTRACT Both erbB3 and IGF-1 receptor (IGF-1R) have been shown to play an important role in trastuzumab resistance. However, it remains unclear whether erbB3- and IGF-1R-initiated signaling pathways possess distinct effects on the sensitivity of lapatinib, a dual tyrosine kinase inhibitor against both EGFR and erbB2, in trastuzumab-resistant breast cancer. Here, we show that the trastuzumab-resistant SKBR3-pool2 and BT474-HR20 breast cancer sublines, as compared the parental SKBR3 and BT474 cells, respectively, exhibit refractoriness to lapatinib. Knockdown of erbB3 inhibited Akt in SKBR3-pool2 and BT474-HR20 cells, significantly increased lapatinib efficacy, and dramatically re-sensitized the cells to lapatinib-induced apoptosis. In contrast, specific knockdown of IGF-1R did not alter the cells’ responsiveness to lapatinib. While the levels of phosphorylated Src (P-Src) were reduced upon IGF-1R downregulation, the P-Akt levels remained unchanged. Furthermore, a specific inhibitor of Akt, but not Src, significantly enhanced lapatinib-mediated anti-proliferative/anti-survival effects on SKBR3-pool2 and BT474-HR20 cells. These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity. Our findings may facilitate the development of precision therapeutic regimens for erbB2-positive breast cancer patients who become resistant to erbB2-targeted therapy.
No takes yet. Share an insight, caveat, or question.
Lyu et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: